Montelukast vs Tildrakizumab

## Montelukast vs Tildrakizumab: Overview

This comparison examines the pharmacological differences between **Montelukast** and **Tildrakizumab**.

## Mechanism of Action

**Montelukast**: Selective leukotriene D4 receptor antagonist.

## Pharmacokinetics

**Half-life**: Montelukast — 2.7-5.5 hours; Tildrakizumab — N/A.

## Chemical Properties

**Molecular Formula**: Montelukast — C35H36ClNO3S; Tildrakizumab — N/A.

**Molecular Weight**: Montelukast — 586.1800 g/mol; Tildrakizumab — N/A.

**Type**: Montelukast — Small molecule; Tildrakizumab — Antibody.